Journey Colab, founded with a mission to revolutionize mental health treatment, focuses on developing FDA-approved psychedelic therapies. The organization aims to harness the promising science behind psychedelics to provide durable remission for individuals suffering from addiction. Their first compound in development is mescaline, and they plan to build a portfolio of plant-identical compounds. Journey Colab integrates psychedelic therapies with psychotherapy and community support to create a comprehensive model of addiction care.
Notable investors back Journey Colab, reflecting confidence in its innovative approach. The organization has made significant strides in real-world research on psychedelic therapeutics, positioning itself as a leader in the emerging field of psychedelic medicine. By pursuing FDA approval and developing effective treatments, Journey Colab aims to make a substantial impact on both individual mental health and broader community well-being.
